UNIDAD EJECUTORA DE ESTUDIOS EN NEUROCIENCIAS Y SISTEMAS COMPLEJOS
Unidad Ejecutora - UE
Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina
REY RD; QUARRACINO C; RODRIGUEZ GE; BENDERSKY, MARIANA
ACTA NEUROLOGICA BELGICA
ACTA MEDICA BELGICA
Since 2015, edaravone is the second drug available for the treatment of Amyotrophic lateral sclerosis (ALS). In this study we analyzed the characteristics and experience of ALS patients treated with this new medication in our country. Sixteen ALS patients were treated with edaravone infusions in three ALS clinics. Most of them were male, had a spinal onset of the disease and a definite diagnosis of ALS. Mean age at first infusion was 53.5 years. Since the diagnosis of ALS, delay in starting treatment with edaravone was five times greater than that of riluzole. Edaravone therapy was usually initiated at a health care facility and was followed by domiciliary cycles. Adverse effects and the need of a special catheter for infusion were rare. Access to edaravone through health insurance was possible in only 43.8% of patients. Altogether, treatment access was limited but feasible and edaravone was well tolerated.